Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 12 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tirzepatide improves HbA1c via weight loss in type 2 diabetes.
Última actualización 4 de julio de 2026
Key finding
The difference in mean HbA1c change from baseline at 40 weeks between tirzepatide and the placebo group ranged from -20.0 to -14.6 mmol/mol.
The study investigated the effects of tirzepatide on HbA1c levels, highlighting the role of weight loss in these reductions.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of tirzepatide on HbA1c levels, highlighting the role of weight loss in these reductions.
Clinical relevance
This study is significant as it highlights the dual mechanism of tirzepatide in managing diabetes, emphasizing the importance of weight loss in achieving better glycemic control. Understanding these effects can help healthcare providers tailor treatment plans for patients with type 2 diabetes.
Keep in mind
Effectiveness data was unclear for some outcomes. The study's population may not be representative of all diabetes patients. Long-term effects beyond 40 weeks were not assessed.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Tina V, Maciej TM, Palash S, Vivian TT, Krishna KC, Jacek K. Tirzepatide-induced HbA1c reductions are mediated through weight loss effects. Diabetes, Obesity & Metabolism. 2025;27(10):5498-5505. doi:10.1111/dom.16592
Efectos Principales
Tirzepatide reduced HbA1c levels by -20.0 to -14.6 mmol/mol compared to placebo.
Weight loss accounted for 12%-27% of the HbA1c reduction when tirzepatide was used alone.
25%-45% of the HbA1c difference between tirzepatide and semaglutide was independent of weight loss.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and HbA1c, Weight loss dependent effect on HbA1c, Weight loss independent effect on HbA1c.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- HbA1c
- Weight loss dependent effect on HbA1c
- Weight loss independent effect on HbA1c
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
3
Evidence pairs
369
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Tema de evidencia
HbA1c Reduction
Guardar evidencia
Tema de evidencia
GLP-1 Receptor Agonists
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Weight loss dependent effect on HbA1c
Tirzepatide → Weight loss dependent effect on HbA1c
Tirzepatide → Weight loss dependent effect on HbA1c
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerWeight loss independent effect on HbA1c
Tirzepatide → Weight loss independent effect on HbA1c
Tirzepatide → Weight loss independent effect on HbA1c
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Tirzepatide led to a significant HbA1c reduction of -20 mmol/mol.
- Weight loss mediated 12%-27% of the HbA1c changes.
- Differences in HbA1c between tirzepatide and semaglutide were partly independent of weight loss.
A quién se aplica
- Adults with type 2 diabetes.
- Patients seeking weight loss alongside glycemic control.
Tener en Cuenta
- The study's findings may not apply to younger populations.
- Results are based on a specific treatment duration of 40 weeks.
- Further research is needed to explore long-term effects.
Entre Líneas
- Effectiveness data was unclear for some outcomes.
- The study's population may not be representative of all diabetes patients.
- Long-term effects beyond 40 weeks were not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Weight loss dependent effect on HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 96
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 12 estudios
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
12 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Weight loss dependent effect on HbA1c Evidence Hub
All studies measuring Weight loss dependent effect on HbA1c
1 studies
outcome_hubMeasures Weight loss dependent effect on HbA1c as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
12 results
All studies on Tirzepatide and Weight loss dependent effect on HbA1c
Intervention: TirzepatideOutcome: Weight loss dependent effect on HbA1c
1 results
All studies on Tirzepatide
Intervention: Tirzepatide
12 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
All studies measuring Weight loss dependent effect on HbA1c
Outcome: Weight loss dependent effect on HbA1c
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Tirzepatide affect weight loss dependent effect on hba1c?
Emerging Evidence
Current evidence does not show a clear benefit of Tirzepatide for Weight loss dependent effect on HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Weight loss dependent effect on HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Tirzepatide affect weight loss independent effect on hba1c?
Emerging Evidence
Current evidence does not show a clear benefit of Tirzepatide for Weight loss independent effect on HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Weight loss independent effect on HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Tirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesTirzepatide improves glycemic control and weight loss in type 2 diabetesTirzepatide improves quality of life in type 2 diabetes patients
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.